Gene Expression and Diagnosis of Diabetes

糖尿病的基因表达和诊断

• 批准号: 6691149
• 负责人: Nancy J Olsen
• 金额: $ 12万
• 依托单位: ARTHROCHIP, LLC
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6691149
• 关键词: autoimmune disorder; clinical research; diabetes mellitus; diagnosis design /evaluation; diagnostic tests; gene expression; human subject; hyperglycemia; microarray technology; questionnaires; technology /technique development

DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be typical of other conditions and quite vague. No currently available blood test accurately excludes or includes the possibility of an autoimmune disease in a subject, and a battery of tests and a period of observation are usually required. A single test that could readily distinguish between an autoimmune and non-autoimmune disorder would allow physicians to focus efforts on the specific disease that affects the patient. This is critical for diabetes since the treatments for type I and type II diabetics are completely different. Using microarray technology, we have compared differences in gene expression in peripheral blood mononuclear cells among individuals with four distinct autoimmune diseases, normal control individuals before and after immunization, and individuals with other chronic diseases. We find that each individual with autoimmune disease has a common gene expression signature that is independent of the specific autoimmune disease but is totally distinct from the normal immune response and is not observed in individuals with other chronic diseases. Based on these data, we have developed a simple test for excluding the possibility that a subject has an autoimmune disorder. The main advantage of this test is that it is a quicker and more accurate test than those currently available. This test has thus far distinguished autoimmune patients from others with 100% accuracy. We now want to turn our attention to diabetes. The first goal of this proposal is to collect gene expression data from patients with type I and type II diabetes to design a test with optimal predictive power. The second goal is to validate the test by examining individuals who have hyperglycemia but do not yet carry a clear-cut diagnosis of either type of diabetes. Long-term goals are to use results from microarray experiments to develop tests that have predictive value for the therapeutic management of individuals with autoimmune and non-autoimmune diseases.

描述（由申请人提供）：自身免疫性疾病很难诊断，因为症状可能是其他疾病的典型特征，而且很模糊。目前没有准确排除的血液检查或包括受试者中自身免疫性疾病的可能性，通常需要进行一系列测试和一系列观察。 可以轻松区分自身免疫性和非自动免疫性疾病的单一测试将使医生能够将精力集中在影响患者的特定疾病上。这对于糖尿病至关重要，因为I型和II型糖尿病患者的治疗方法是完全不同的。使用微阵列技术，我们比较了患有四种不同自身免疫性疾病，免疫后和之后的正常对照个体以及患有其他慢性疾病的个体的个体中外周血单核细胞中基因表达的差异。我们发现，每个患有自身免疫性疾病的人都有一个常见的基因表达特征，该特征与特定的自身免疫性疾病无关，但与正常的免疫反应完全不同，在其他慢性疾病的患者中未观察到。基于这些数据，我们开发了一个简单的测试，以排除受试者患有自身免疫性疾病的可能性。该测试的主要优点是，它比当前可用的测试更快，更准确。迄今为止，该测试已将自身免疫性患者与100％准确性的其他患者区分开。现在，我们想将注意力转移到糖尿病上。该提案的第一个目标是从I型和II型糖尿病患者中收集基因表达数据，以设计具有最佳预测能力的测试。第二个目标是通过检查患有高血糖但尚未对任何一种糖尿病的人进行明确诊断的个体来验证测试。长期目标是利用微阵列实验的结果来开发具有自身免疫性和非自动免疫性疾病患者治疗管理的预测价值的测试。